FIGO good practice recommendations for reducing preterm birth and improving child outcomes

TY - JOUR

T1 - FIGO good practice recommendations for reducing preterm birth and improving child outcomes

AU - the FIGO Working Group for Preterm Birth

AU - Jacobsson, Bo

AU - Simpson, Joe Leigh

AU - Jacobsson, Bo

AU - Simpson, Joe Leigh

AU - Norman, Jane

AU - Grobman, William

AU - Bianchi, Ana

AU - Munjanja, Stephen

AU - González, Catalina María Valencia

AU - Mol, Ben W.

AU - Shennan, Andrew

N1 - Funding Information: Ana Bianchi reports no conflicts of interest. Andrew Shennan reports payment/honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Manipal India; support for attending meetings and/or travel from Hologic; leadership or fiduciary roles in the HTA Commissioning Board UK and Action on Pre‐eclampsia charity. Ann‐Beth Moller reports no conflicts of interest. Ben W. Mol reports an investigator grant from NHMRC; consultancy for ObsEva; and research funding from Guerbet, Ferring, and Merck KGaA. Bo Jacobbson reports research grants from Swedish Research Council, Norwegian Research Council, March of Dimes, Burroughs Wellcome Fund and the US National Institute of Health; clinical diagnostic trials on NIPT with Ariosa (completed), Natera (ongoing), Vanadis (completed) and Hologic (ongoing) with expendidures reimbused per patient; clinical probiotic studies with product provided by FukoPharma (ongoing, no funding) and BioGaia (ongoing; also provided a research grant for the specific study); collaboration in IMPACT study where Roche, Perkin Elmer and Thermo Fisher provided reagents to PLGF analyses; coordination of scientific conferences and meetings with commercial partners as such as NNFM 2015, ESPBC 2016 and a Nordic educational meeting about NIPT and preeclampsia screening. Bo Jacobbson is also Chair of the FIGO Working Group for Preterm Birth and the European Association of Perinatal Medicine's special interest group of preterm delivery; steering group member of Genomic Medicine Sweden; chairs the Genomic Medicine Sweden complex diseases group; and is Swedish representative in the Nordic Society of Precision Medicine. Joe Leigh Simpson reports royalties from Springer and Elsevier; consulting fees from the Illumina Clinical Expert Panel 2020; payment or honoraria for lectures, presentations, speakers bureaus, or educational events from the 1st and 2nd International Congresses on the Future of Women's Health, and a speaker's bureau at ASRM 2019; participation on a data safety monitoring board or advisory board for the FDA DSMB; and leadership or fiduciary roles in IFFS and PGDIS. Catalina M. Valencia reports no conflicts of interest. J. Frederik Frøen reports no conflicts of interest. Jane Norman reports receipt of grants from government and charitable bodies for research into understanding the mechanism of term and preterm labour and understanding treatments; participation in a Data Safety and Monitoring Board for a study involving a preterm birth therapeutic agent for GlaxoSmithKline; and consultancy for Dilafor on drugs to alter labour progress. Joe Leigh Simpson reports royalties from Springer and Elsevier; consulting fees from the Illumina Clinical Expert Panel 2020; payment or honoraria for lectures, presentations, speakers bureaus, or educational events from the 1st and 2nd International Congresses on the Future of Women's Health, and a speaker's bureau at ASRM 2019; participation on a data safety monitoring board or advisory board for the FDA DSMB; and leadership or fiduciary roles in IFFS and PGDIS. Kelle Moley reports no conflicts of interest. Lisa Story reports receipt of equipment, materials, drugs, medical writing, gifts or other services from Clinical Innovations. Natalie Suff reports no conflicts of interest. Sarah J. Stock reports research funding from NIHR, Wellcome Trust, Chief Scientist Office Scotland, Tommy's, and Medical Research Council; participation on a Data Safety Monitoring Board or Advisory Board for NIHR‐funded WILL trial and NIHR‐funded Giant Panda; leadership or fiduciary roles for SANDS and RCOG Stillbirth Clinical Studies Group; and receipt of equipment, materials or drugs from Hologic, Medix Biochemica, and Parsogen Diagnostics. Stephen Mujanja reports no conflicts of interest. William Grobman reports no conflicts of interest. Funding Information: The good practice recommendations series work has been supported by grants from March of Dimes to the FIGO Working Group for Preterm Birth.

PY - 2021/10

Y1 - 2021/10

UR - http://www.scopus.com/inward/record.url?scp=85115068440&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85115068440&partnerID=8YFLogxK

U2 - 10.1002/ijgo.13863

DO - 10.1002/ijgo.13863

M3 - Editorial

C2 - 34520060

AN - SCOPUS:85115068440

VL - 155

SP - 1

EP - 4

JO - International Journal of Gynecology and Obstetrics

JF - International Journal of Gynecology and Obstetrics

SN - 0020-7292

IS - 1

ER -